Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,009 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
Pollack CV Jr, Bernstein R, Dubiel R, Reilly P, Gruenenfelder F, Huisman MV, Kam CW, Kleine E, Levy JH, Sellke FW, Steiner T, Ustyugova A, Weitz JI. Pollack CV Jr, et al. Among authors: steiner t. J Med Econ. 2017 May;20(5):435-442. doi: 10.1080/13696998.2016.1273229. Epub 2017 Jan 17. J Med Econ. 2017. PMID: 27981865 Free article. Clinical Trial.
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Pollack CV Jr, Levy JH, Eikelboom J, Weitz JI, Sellke FW, Huisman MV, Steiner T, Kamphuisen P, Bernstein RA. Pollack CV Jr, et al. Among authors: steiner t. Am J Emerg Med. 2014 Nov;32(11):1433-4. doi: 10.1016/j.ajem.2014.08.072. Epub 2014 Aug 29. Am J Emerg Med. 2014. PMID: 25239691 No abstract available.
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI. Pollack CV Jr, et al. Among authors: steiner t. Thromb Haemost. 2015 Jul;114(1):198-205. doi: 10.1160/TH15-03-0192. Epub 2015 May 28. Thromb Haemost. 2015. PMID: 26020620 Clinical Trial.
Idarucizumab for Dabigatran Reversal.
Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Pollack CV Jr, et al. Among authors: steiner t. N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22. N Engl J Med. 2015. PMID: 26095746 Free article. Clinical Trial.
Letter to the Editor: Managing Dabigatran-Related Bleeding.
Levy JH, Weitz JI, Bernstein RA, Eikelboom J, Hylek E, Huisman MV, Reilly PA, Steiner T, Kamphuisen P, Kam CW, Pollack CV Jr. Levy JH, et al. Among authors: steiner t. J Intensive Care Med. 2016 Jan;31(1):70-1. doi: 10.1177/0885066614542758. J Intensive Care Med. 2016. PMID: 26663474 No abstract available.
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Pollack CV Jr, et al. Among authors: steiner t. N Engl J Med. 2017 Aug 3;377(5):431-441. doi: 10.1056/NEJMoa1707278. Epub 2017 Jul 11. N Engl J Med. 2017. PMID: 28693366 Free article. Clinical Trial.
1,009 results